Sofosbuvir in the treatment of chronic hepatitis C: New dog, new tricks

Clinical Infectious Diseases

Volumn 59, Issue 3, 2014, Pages 411-415

  Abraham, George M ^a   Spooner, Linda M ^b  

^a SAINT VINCENT HOSPITAL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

HCV; Hepatitis C; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; SOFOSBUVIR; VIRAL PROTEIN;

ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN; SOFOSBUVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84904966999     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu265     Document Type: Article

References (18)

1. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, & TB Prevention. Viral hepatitis statistics and surveillance - United States, 2011. Available at: http://www.cdc.gov/hepatitis/statistics/. Accessed 21 November 2013.
2. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis 2013; 56: 40-50.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype chronic hepatitis C infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
5. Sovaldi (sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences, Inc, 2013.
6. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58: 663-8.
7. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.
8. Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-9.
9. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-78.
10. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
11. Food and Drug Administration Antiviral Drugs Advisory Committee. Briefing document: sofosbuvir for treatment of chronic hepatitis C infection, 2013. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371877.pdf. Accessed 18 December 2013.
12. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
13. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
14. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial [abstract 1085]. In: Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 2013.
15. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) [abstract 212]. In: Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 2013.
16. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label randomised, phase 2 trial. Lancet 2014; 383: 515-23.
17. Red Book. Ann Arbor, MI: Truven Health Analytics, 2014.
18. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59: 1692-1705.